Etiology, pathogenesis, diagnosis and treatment of oral submucous fibrosis

• Main Authors: JIAN Xinchun, GAO Xing
• Format: Article
• Language: zho
• Published: Editorial Department of Journal of Prevention and Treatment for Stomatological Diseases 2021-04-01
• Series: 口腔疾病防治
• Subjects: oral submucous fibrosis; oral precancerous lesion; oral potentially malignant disorders; oral mucous disease; limited mouth opening; therapeutic interventions; triamcinolone acetonide; tanshinone
• Online Access: http://www.kqjbfz.com/CN/10.12016/j.issn.2096-1456.2021.04.001
• ISSN: 2096-1456; 2096-1456

Oral submucous fibrosis (OSF) is a chronic disease that produces scars, tissue fibrosis, and precancerous lesions. Epidemiological studies have shown that chewing betel nut is the most significant risk factor for OSF. Many studies have also indicated that habits such as chewing and smoking tobacco and drinking alcohol increase the risk of OSF, which is widely recognized as an oral precancerous lesion or a potentially malignant oral disorder. Pathological characteristics include chronic inflammation, excessive collagen deposition in the connective tissues below the oral mucous epithelium and local inflammation in the lamina propria or deep connective tissues. OSF patients have a 7%~30% chance of developing oral cancer. Submucosal local injection of triamcinolone and tanshinone was mainly used for the treatment of oral submucosal fibrosis. This treatment improves mouth opening and alleviates the burning sensation in OSF, and the treatment efficacy was as high as 93%. The article will discuss the occurrence, development, diagnosis and treatment of oral submucous fibrosis for clinical management by the medical community.